Britain's state-funded National Health Service (NHS) was accused of cover up in an infected blood scandal dating back to the 1970s in a public inquiry report submitted to the government on Monday. Prime Minister Rishi Sunak is expected to issue an apology on behalf of the government after inquiry chair Sir Brian Langstaff delivered his scathing verdict on the issue, which involves over 30,000 people being infected with life-threatening viruses such as HIV and Hepatitis C while they were under NHS care between the 1970s and 1990s. It involves infected batches of Factor VIII, an essential blood clotting protein which haemophiliacs do not produce naturally, imported from the US and used widely to treat patients at the time. They were infected as donated blood was not tested for HIV/AIDS until 1986 and Hepatitis C until 1991 in the UK. The scale of what happened is horrifying. The most accurate estimate is that more than 3,000 deaths are attributable to infected blood, blood products an
ICICI Prudential MF, Aditya Birla Sun Life MF among top buyers
There is a need to increase the number of qualified doctors to more than 50 lakh and also add 30 lakh more hospital beds in the country in order to achieve India's healthcare vision 2047, according to a report. The increase in the number of doctors and beds in hospitals would help India get closer to the average of developed countries, as per a FICCI-EY Report titled 'Decoding India's Healthcare Landscape'. India has witnessed a significant increase in the number of medical colleges and MBBS seats, addressing the growing demand for healthcare professionals, it said. The number of registered allopathic doctors witnessed substantial growth, rising from 6,60,801 in 2005 to 13,08,009 such doctors in 2022, the report said. Similarly, the bed capacity in government hospitals across India has consistently grown from 4.7 lakh beds in 2005 to 8.5 lakh beds in 2021. The report also highlighted the importance of having 100 per cent health insurance coverage for the country's population. It
Smallcap funds raked in net inflows of Rs 2,209 crore in April amid a sharp rally in smallcap shares
For the full year of FY24, the company posted a 14 per cent Y-o-Y decline in PAT and the revenue grew by 3.2 per cent reaching Rs 266.9 crore and Rs 2,327.8 crore respectively
Manipal Hospitals, which acquired an 84 per cent stake in AMRI Hospitals in September 2023 for around Rs 2,300 crore, announced brand integration on Tuesday
Rise in median age and ageing population to fuel increase in demand for senior housing
AstraZeneca Covid vaccine row: As of April 30, 2024, over 1.7 billion doses of the Covishield vaccine has been administered in India
75% of PE-VC investments were directed towards conventional sectors such as healthcare, retail, energy, advanced manufacturing
The hospital group also claims that the ERP program improves the survival rate of the patients by approximately 2-3 per cent while enhancing patient outcomes through advanced techniques
Procter & Gamble Health on Thursday said its profit after tax declined 21 per cent year-on-year to Rs 46 crore for the third quarter ended March 2024. The company, which follows the July-June financial year, reported a profit after tax (PAT) of Rs 59 core a year ago. Its revenue from operations declined to Rs 252 crore for the period under review compared to Rs 321 crore in the year-ago period, Procter & Gamble (P&G) Health said in a regulatory filing. "The company's continued efforts to strengthen our reach and distribution with a transformed go-to-market model reflected in a one-time impact on the quarter's sales owing to the transition and optimisation of trade management and inventory," P&G Health India Managing Director Milind Thatte said. "However, we have seen sales recover in the months of March and April," he added.
The company reached a $1.1 billion settlement for CPAP machine lawsuits in US
Similar to the CoWIN portal for covid-19, the government's U-WIN platform registers and tracks routine vaccination and immunisation
Former ICMR scientist Raman Gangakhedkar said the risk is highest after the initial dose, eventually decreasing with subsequent doses
Manufactured first in 2021, the AstraZeneca vaccine, known in India as Covishield, has been facing scrutiny over the years, with many countries banning it back in 2021 itself
Many industry bodies too had become party to the case, urging the apex court to listen to their grievances as well
AstraZeneca has admitted for the first time in court documents that its Covid vaccine can cause rare side effects, marking an about-turn that may open the door for a multi-million pound legal payout
The hospital and Chennai-based NGO helped Pakistani family settle bill of more than Rs 35 lakh for the transplant
Linking deadline will from June 30 extended to 120 days, from 30 days now
The expected revenue growth in FY25 comes on the back of an estimated 14% growth in the last financial year